65 related articles for article (PubMed ID: 27037906)
1. Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy.
Beyar-Katz O; Magidey K; Ben-Tsedek N; Alishekevitz D; Timaner M; Miller V; Lindzen M; Yarden Y; Avivi I; Shaked Y
J Pathol; 2016 Jul; 239(3):262-73. PubMed ID: 27037906
[TBL] [Abstract][Full Text] [Related]
2. To b(ortezomib) or not to be: the stroma's the thing.
Krem MM; Yan J
J Pathol; 2016 Oct; 240(2):123-5. PubMed ID: 27340009
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma.
Marino S; Petrusca DN; Bishop RT; Anderson JL; Sabol HM; Ashby C; Layer JH; Cesarano A; Davé UP; Perna F; Delgado-Calle J; Chirgwin JM; Roodman GD
Haematologica; 2024 May; 109(5):1501-1513. PubMed ID: 37981834
[TBL] [Abstract][Full Text] [Related]
4. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.
Chauhan D; Singh AV; Aujay M; Kirk CJ; Bandi M; Ciccarelli B; Raje N; Richardson P; Anderson KC
Blood; 2010 Dec; 116(23):4906-15. PubMed ID: 20805366
[TBL] [Abstract][Full Text] [Related]
5. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma.
Federico C; Alhallak K; Sun J; Duncan K; Azab F; Sudlow GP; de la Puente P; Muz B; Kapoor V; Zhang L; Yuan F; Markovic M; Kotsybar J; Wasden K; Guenthner N; Gurley S; King J; Kohnen D; Salama NN; Thotala D; Hallahan DE; Vij R; DiPersio JF; Achilefu S; Azab AK
Nat Commun; 2020 Nov; 11(1):6037. PubMed ID: 33247158
[TBL] [Abstract][Full Text] [Related]
6. Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs.
Liu X; Moscvin M; Oh S; Chen T; Choi W; Evans B; Rowell SM; Nadeem O; Mo CC; Sperling AS; Anderson KC; Yaqoob Z; Bianchi G; Sung Y
Clin Exp Med; 2023 Nov; 23(7):3821-3832. PubMed ID: 37421589
[TBL] [Abstract][Full Text] [Related]
7. Targeting the β
Satilmis H; Verheye E; Vlummens P; Oudaert I; Vandewalle N; Fan R; Knight JM; De Beule N; Ates G; Massie A; Moreaux J; Maes A; De Bruyne E; Vanderkerken K; Menu E; Sloan EK; De Veirman K
J Pathol; 2023 Jan; 259(1):69-80. PubMed ID: 36245401
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.
Jakubowiak A; Offidani M; Pégourie B; De La Rubia J; Garderet L; Laribi K; Bosi A; Marasca R; Laubach J; Mohrbacher A; Carella AM; Singhal AK; Tsao LC; Lynch M; Bleickardt E; Jou YM; Robbins M; Palumbo A
Blood; 2016 Jun; 127(23):2833-40. PubMed ID: 27091875
[TBL] [Abstract][Full Text] [Related]
9. Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse.
Reyal Y; Popat R; Cheesman S; Rismani A; D'Sa S; Rabin N; Yong K
Br J Haematol; 2017 May; 177(3):495-497. PubMed ID: 27062387
[No Abstract] [Full Text] [Related]
10. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
Gupta N; Labotka R; Liu G; Hui AM; Venkatakrishnan K
Invest New Drugs; 2016 Jun; 34(3):338-46. PubMed ID: 27039387
[TBL] [Abstract][Full Text] [Related]
11. Abnormal IGF-Binding Protein Profile in the Bone Marrow of Multiple Myeloma Patients.
Bieghs L; Brohus M; Kristensen IB; Abildgaard N; Bøgsted M; Johnsen HE; Conover CA; De Bruyne E; Vanderkerken K; Overgaard MT; Nyegaard M
PLoS One; 2016; 11(4):e0154256. PubMed ID: 27111220
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence.
Abid MB; De Mel S; Abid MA; Tan KB; Chng WJ
Cancer Biol Ther; 2016 Jul; 17(7):723-6. PubMed ID: 27105248
[TBL] [Abstract][Full Text] [Related]
13. miR-320a regulates cell proliferation and apoptosis in multiple myeloma by targeting pre-B-cell leukemia transcription factor 3.
Lu Y; Wu D; Wang J; Li Y; Chai X; Kang Q
Biochem Biophys Res Commun; 2016 May; 473(4):1315-1320. PubMed ID: 27086852
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based Regimens.
Hyun SY; Han SH; Kim SJ; Jang JE; Kim Y; Cho H; Lee JY; Cheong JW; Min YH; Song JW; Kim JS
J Korean Med Sci; 2016 Apr; 31(4):510-8. PubMed ID: 27051233
[TBL] [Abstract][Full Text] [Related]
15. BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth.
Deng J; Park D; Wang M; Nooka A; Deng Q; Matulis S; Kaufman J; Lonial S; Boise LH; Galipeau J; Deng X
Oncotarget; 2016 May; 7(19):27753-63. PubMed ID: 27049723
[TBL] [Abstract][Full Text] [Related]
16. The lack of Lazarus effect with proteasome inhibition.
Marks SD
Pediatr Nephrol; 2016 Aug; 31(8):1217-9. PubMed ID: 27048227
[TBL] [Abstract][Full Text] [Related]
17. Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth.
Mao SPH; Park M; Cabrera RM; Christin JR; Karagiannis GS; Oktay MH; Zaiss DMW; Abrams SI; Guo W; Condeelis JS; Kenny PA; Segall JE
Breast Cancer Res; 2018 Oct; 20(1):131. PubMed ID: 30367629
[TBL] [Abstract][Full Text] [Related]
18. Production of amphiregulin and recovery from influenza is greater in males than females.
Vermillion MS; Ursin RL; Kuok DIT; Vom Steeg LG; Wohlgemuth N; Hall OJ; Fink AL; Sasse E; Nelson A; Ndeh R; McGrath-Morrow S; Mitzner W; Chan MCW; Pekosz A; Klein SL
Biol Sex Differ; 2018 Jul; 9(1):24. PubMed ID: 30012205
[TBL] [Abstract][Full Text] [Related]
19. Transgenic mice specifically expressing amphiregulin in white adipose tissue showed less adipose tissue mass.
Yang B; Kumoto T; Arima T; Nakamura M; Sanada Y; Kumrungsee T; Sotomaru Y; Shimada M; Yanaka N
Genes Cells; 2018 Mar; 23(3):136-145. PubMed ID: 29341420
[TBL] [Abstract][Full Text] [Related]
20. Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group.
Bila J; Katodritou E; Guenova M; Basic-Kinda S; Coriu D; Dapcevic M; Ibricevic-Balic L; Ivanaj A; Karanfilski O; Zver S; Beksac M; Terpos E; Dimopoulos MA
J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
